We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Orphazyme A/s | LSE:0CUM | London | Ordinary Share | DK0062502894 | ORPHAZYME ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 61,590.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 17.87M | 26.07M | 0.7383 | 121.90 | 3.18B |
From May 2022 to May 2024
Company announcement Orphazyme A/SNo. 05/2023 Ole Maaløes Vej 3DK-2200 Copenhagen N www.orphazyme.comCompany Registration No. 32266355
Copenhagen, Denmark, May 9, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Nordic Compound Invest A/S that Nordic Compound Invest A/S holds shares, corresponding to more than 5% of the total share capital and voting rights in the Company.
For additional information, please contact
Orphazyme A/S
Anders Vadsholt, Chief Executive Officer and Chief Financial Officer: +45 28 98 90 55
Attachment
1 Year Orphazyme A/s Chart |
1 Month Orphazyme A/s Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
